Best Online Weight Loss Programs of 2026
Online weight-loss programs span everything from app-only coaching to full clinical protocols with GLP-1 prescriptions, the most effective of which are backed by the STEP 1 trial (NEJM 2021, 14.9% weight loss) and SURMOUNT-1 trial (NEJM 2022, 20.9% weight loss). We scored each on the value of what is included at the entry price, the quality of clinical support, and the breadth of medication options if a patient needs to escalate beyond lifestyle changes.
Reader-supported, we may earn a commission through links on this site. Rankings are editorially independent. Disclosure · Methodology
Online weight loss programs span a wide spectrum — from GLP-1 prescription services to behavioural coaching platforms to hybrid programs that combine medication with structured lifestyle support. The clinical evidence base for GLP-1 medications is now robust: the STEP 1 trial (NEJM 2021) and SURMOUNT-1 trial (NEJM 2022) established that pharmacological approaches produce meaningfully larger weight loss than lifestyle intervention alone.
The best online programs are those that combine a clear medication pathway with genuine clinical oversight — not just a questionnaire that auto-generates a prescription. The programs ranked here were evaluated on whether they offer a licensed prescriber relationship, transparent all-in pricing (program fee plus medication cost), and a coherent follow-up protocol for dose titration and side-effect management.
This list focuses on programs that are accessible to most US adults without insurance, since GLP-1 coverage remains inconsistent across commercial plans. If your insurance covers Wegovy or Zepbound, your first call should be to your primary care provider — telehealth programs add the most value for patients who are paying out of pocket.
The Ranking
WellMedr
A multi-category telehealth platform with compounded semaglutide shown from $49/mo and tirzepatide from $89/mo on 12-month plans, plus a 4.6/5 Trustpilot record.
Editor’s take: WellMedr is a value-led option for people who want compounded GLP-1 access plus the convenience of additional men's-health and hair-loss categories under one account. Its public Trustpilot profile displayed a 4.6/5 rating from 1,963 reviews when checked September 27, 2026. The current checkout showed semaglutide at $49/mo on a prepaid 12-month term and $99 month to month, while tirzepatide was $89/mo on a prepaid 12-month term and $129 month to month. Compounded medications are not FDA-approved finished drugs; confirm the exact prescription, pharmacy, dose progression, cancellation terms and total commitment with the clinician before paying.
Full review →
SkinnyRx
Clinician-guided GLP-1 platform with both compounded and brand-name access plus overnight shipping.
Editor’s take: Premium positioning, premium catalog. If you want maximum optionality across GLP-1 modalities, this is the deepest menu on the site. The premium catalog comes at a premium price. If you want maximum optionality across GLP-1 modalities, SkinnyRx is the deepest menu on the site; if you want the lowest cost, look at Trimi or HealthRx.
Full review →
Direct Meds
Compounded GLP-1 clinic with transparent pricing and dedicated nurse support.
Editor’s take: Direct Meds is easier to compare than a program that separates its membership fee from medication, provided the public $249 and $297 starting points match the treatment path you are offered. Skip it if you specifically want brand-name GLP-1 access or in-state pickup.
Full review →
Shed Rx
GLP-1 clinic offering injections, oral semaglutide, drops, and lozenges plus brand-name Wegovy and Zepbound.
Editor’s take: A reasonable mid-priced pick when delivery flexibility matters. Verify auto-billing terms before signing up given mixed reports. Verify auto-billing terms before signing up given mixed reviews on cancellation. If delivery flexibility is your priority, compare ShedRx against Breeze Meds which also offers sublingual tirzepatide.
Full review →
Women-focused telehealth combining compounded GLP-1 weight loss with HRT support.
Editor’s take: A focused women's health pick. If you only want GLP-1, you'll find cheaper; if you want both GLP-1 and HRT in one clinic, this is one of the cleanest options on the list. If you only want GLP-1 without hormonal support, a lower-cost specialist like Trimi or HealthRx will be more cost-effective. If you want both GLP-1 and HRT in one clinic, Gala Health is one of the cleanest options available.
Full review →
FuturHealth
GLP-1 weight-loss platform combined with personalised nutrition and fitness coaching.
Editor’s take: Coaching is the differentiator. If you're going to use it, FuturHealth pulls ahead of cheaper, drug-only competitors. If you won't, save the money.
Full review →
Flexible, medically guided compounded GLP-1 weight loss with transparent monthly pricing.
Editor’s take: Honest, simple, and focused. No brand-name GLP-1 access is the main trade-off, but for cost-conscious first-time users who just want a guided compounded GLP-1 program without upsells or complexity, that trade-off is rational. Transparent monthly pricing with no hidden fees is a genuine differentiator in a category where pricing opacity is common.
Full review →
Refills
Multi-category telehealth platform covering GLP-1, ED, hair loss, and longevity peptides with no membership fees and flat dosage pricing.
Editor’s take: A versatile multi-category platform with a competitive GLP-1 entry price and no dose-tier price increases. The breadth of treatments (GLP-1, ED, hair, longevity) makes it a practical single-provider option, though the FDA warning letter regarding compounded semaglutide advertising is worth noting.
Full review →2026 Price Comparison. All-In Monthly Cost
Prices verified June 2026· How we verify →Published monthly price terms at the lowest listed rate and higher listed rate. Read each provider’s terms note because medication, consult, shipping, and plan-length conditions vary.
Prices are verified from public provider websites and may change. Compounded medications are from 503A pharmacies operating under personalisation exceptions. Always confirm pricing and legal status directly with the provider before purchase.
| Provider | Starting dose | Maintenance dose | Pharmacy | Trustpilot | Verified | Actions |
|---|---|---|---|---|---|---|
Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month. | $49/mo | $99 – $129/mo | 503A | 4.6 | Aug 11 | |
TrimiLowest Flat Rate Flat rate at every dose | $99/mo | $125/mo | 503A | 4.7 | June 2026 | |
| $99/mo | $249/mo | 503A | 4.3 | June 2026 | ||
| $149/mo | $249/mo | 503A | 4.8 | June 2026 | ||
Includes coaching | $198/mo | $299/mo | 503A | 4.7 | June 2026 |
Semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
- Starting dose
- $49/mo
- Maintenance dose
- $99 – $129/mo
- Pharmacy
- 503A
- Price checked
- Aug 11
- Starting dose
- $99/mo
- Maintenance dose
- $125/mo
- Pharmacy
- 503A
- Price checked
- June 2026
- Starting dose
- $99/mo
- Maintenance dose
- $249/mo
- Pharmacy
- 503A
- Price checked
- June 2026
- Starting dose
- $149/mo
- Maintenance dose
- $249/mo
- Pharmacy
- 503A
- Price checked
- June 2026
Includes coaching
- Starting dose
- $198/mo
- Maintenance dose
- $299/mo
- Pharmacy
- 503A
- Price checked
- June 2026
All prices are all-in (consult + medication + shipping) unless noted. Prices verified June 2026. Compounded medications are not FDA-approved finished products. They are compounded under 503A personalisation exceptions. Click any provider name to read the full independent review. CTA buttons link to provider websites and may earn us a commission. How we verify prices →
Methodology
Programs were judged on entry price, included consultations, formulary depth (oral and injectable), shipping cadence, and provider availability.
The Online Weight-Loss Landscape: Beyond the GLP-1 Headlines
Telehealth weight loss is dominated by GLP-1 marketing, but the category is broader than Wegovy and Zepbound — and for some patients, an older oral medication, a behavioral coaching program, or a combination protocol is a better fit than the headline injectable. Below is how we frame the landscape for readers trying to figure out where they actually fit.
Who Actually Needs a GLP-1 — and Who Doesn't
GLP-1 medications are FDA-approved for chronic weight management in adults with a BMI of 30 or above, or a BMI of 27+ with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia). The trials that established efficacy enrolled this population specifically. For patients with a BMI in the overweight range without comorbidities — say, someone at 28 BMI who wants to lose 15 pounds for a wedding — GLP-1s are technically off-label and the cost-benefit is meaningfully different.
For patients in that lower-acuity range, a structured behavioral coaching program (with or without a non-GLP-1 medication like phentermine or contrave) often produces 5-10% weight loss at much lower cost and with a much shorter side-effect profile. The data is unambiguous that GLP-1s produce more weight loss than other modalities — but 'more weight loss' isn't the only goal, and the price differential is substantial.
Phentermine, Contrave, and Why Older Medications Still Have a Place
Phentermine has been FDA-approved for weight loss since 1959 and remains the most-prescribed weight-loss medication in the United States. It produces an average 5% weight loss over 12 weeks of short-term use and costs $10-30/month. Contrave (naltrexone/bupropion) produces roughly 4-6% weight loss over 12 months and costs $99-$200/month. Topiramate, while not FDA-approved for weight loss alone, is a component of Qsymia and is widely prescribed off-label.
These older medications have known limitations: phentermine is a controlled substance with cardiovascular contraindications; contrave can interact with multiple psychiatric medications; topiramate causes cognitive side effects in a meaningful minority of users. They are not interchangeable with GLP-1s, but they are options — and a serious telehealth weight-loss clinic should at least mention them rather than funnel every patient toward the most expensive injectable.
What Coaching-Plus-Medication Adds
There is a long debate in obesity medicine about whether behavioral support meaningfully adds to medication effects. Recent meta-analyses suggest the answer is yes — patients who pair GLP-1 therapy with structured nutrition and habit support lose roughly 2-4% more body weight than medication-only patients, and they regain less when therapy is paused or discontinued.
Whether that incremental effect is worth the extra $50-150/month a coaching tier costs depends on whether the patient is the kind of person who benefits from accountability infrastructure. Patients who are already disciplined eaters often find structured coaching unnecessary; patients who struggle with emotional eating, irregular meals, or sustained exercise habits typically get real value. It's worth asking yourself which group you're in before paying for the upgrade.
The right starting point for online weight-loss therapy depends on your BMI, your comorbidity profile, your budget, and how you respond to behavior support. The decision helper at the top of this page maps the most common patient profiles to specific clinics, but the broader point is that 'online weight loss' is not synonymous with 'GLP-1 prescription' — it's worth asking whether a different protocol is a better fit before defaulting to the most heavily marketed one.
What the Studies Actually Show
The medication-led programs on this list dispense one of two active ingredients: semaglutide or tirzepatide. The figures below summarise the head-to-head Phase 3 evidence on which the obesity-management approvals rest.
| Endpoint | Finding |
|---|---|
| Mean weight loss (STEP 1, 68 weeks, 2.4 mg)1 | −14.9% body weight vs −2.4% placebo in adults with overweight/obesity without diabetes |
| Cardiovascular outcomes (SELECT, ~40 months)2 | 20% relative risk reduction in major adverse cardiovascular events (MACE) in adults with established CV disease and overweight/obesity |
| GI side effects (FDA prescribing information)3 | Nausea ≥10%, diarrhea ≥10%, vomiting ≥10%, constipation ≥10%; most cases mild–moderate and dose-dependent |
| Mean weight loss (SURMOUNT-1, 72 weeks, 15 mg)6 | −20.9% body weight vs −3.1% placebo in adults with obesity without diabetes |
| Mean weight loss with T2D (SURMOUNT-2, 72 weeks, 15 mg)7 | −14.7% body weight in adults with type 2 diabetes |
| Sleep apnea (SURMOUNT-OSA)8 | Tirzepatide reduced apnea-hypopnea index (AHI) by ~25–29 events/hour vs placebo at 52 weeks; FDA-approved labeling for moderate-to-severe OSA in obesity |
Frequently Asked Questions
- STEP 1 — NEJM 2021 · Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med 2021;384:989–1002.
- SELECT — NEJM 2023 · Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med 2023;389:2221–2232.
- FDA Prescribing Information — Wegovy (semaglutide) · WEGOVY (semaglutide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SUSTAIN program — ADA scientific summary · Aroda VR, Ahmann A, Cariou B, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1–7 clinical trials. Diabetes Obes Metab 2019;21(7):1601–1613.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
- SURMOUNT-1 — NEJM 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 2022;387:205–216.
- SURMOUNT-2 — Lancet 2023 · Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 2023;402(10402):613–626.
- SURMOUNT-OSA — NEJM 2024 · Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193–1205.
- FDA Prescribing Information — Zepbound (tirzepatide) · ZEPBOUND (tirzepatide) injection, for subcutaneous use. U.S. Food and Drug Administration prescribing information.
- SURPASS — program summary · Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503–515.
- FDA — Compounding and the FDA: Questions and Answers · U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers (last updated 2024).
RxNotebook is an editorial publication. Citations point to peer-reviewed journals, FDA labeling, and clinical society guidelines. We are not affiliated with the studies cited above. This page is for general information and is not medical advice.
Compare Top Providers
- bmiMD vs SkinnyRx (2026): Which Compounded GLP-1 Clinic Wins?
- FuturHealth vs Found (2026): GLP-1 + Coaching Compared
- Sesame Care vs Found (2026): Pay-Per-Visit vs Subscription GLP-1
- bmiMD vs FuturHealth (2026): Compounded GLP-1 Clinic Comparison
- TrimRx vs FuturHealth (2026): Brand-Name vs Coaching-First GLP-1
- SkinnyRx vs FuturHealth (2026): Oral GLP-1 vs Coaching-First Platform